Literature DB >> 24642057

Involvement of a volatile metabolite during phosphoramide mustard-induced ovotoxicity.

Jill A Madden1, Patricia B Hoyer2, Patrick J Devine3, Aileen F Keating4.   

Abstract

The finite ovarian follicle reserve can be negatively impacted by exposure to chemicals including the anti-neoplastic agent, cyclophosphamide (CPA). CPA requires bioactivation to phosphoramide mustard (PM) to elicit its therapeutic effects however; in addition to being the tumor-targeting metabolite, PM is also ovotoxic. In addition, PM can break down to a cytotoxic, volatile metabolite, chloroethylaziridine (CEZ). The aim of this study was initially to characterize PM-induced ovotoxicity in growing follicles. Using PND4 Fisher 344 rats, ovaries were cultured for 4 days before being exposed once to PM (10 or 30 μM). Following eight additional days in culture, relative to control (1% DMSO), PM had no impact on primordial, small primary or large primary follicle number, but both PM concentrations induced secondary follicle depletion (P<0.05). Interestingly, a reduction in follicle number in the control-treated ovaries was observed. Thus, the involvement of a volatile, cytotoxic PM metabolite (VC) in PM-induced ovotoxicity was explored in cultured rat ovaries, with control ovaries physically separated from PM-treated ovaries during culture. Direct PM (60 μM) exposure destroyed all stage follicles after 4 days (P<0.05). VC from nearby wells depleted primordial follicles after 4 days (P<0.05), temporarily reduced secondary follicle number after 2 days, and did not impact other stage follicles at any other time point. VC was determined to spontaneously liberate from PM, which could contribute to degradation of PM during storage. Taken together, this study demonstrates that PM and VC are ovotoxicants, with different follicular targets, and that the VC may be a major player during PM-induced ovotoxicity observed in cancer survivors.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Chloroethylaziridine; Ovotoxicity; Phosphoramide mustard

Mesh:

Substances:

Year:  2014        PMID: 24642057      PMCID: PMC4077164          DOI: 10.1016/j.taap.2014.03.006

Source DB:  PubMed          Journal:  Toxicol Appl Pharmacol        ISSN: 0041-008X            Impact factor:   4.219


  27 in total

1.  Protective role for ovarian glutathione S-transferase isoform pi during 7,12-dimethylbenz[a]anthracene-induced ovotoxicity.

Authors:  Poulomi Bhattacharya; Aileen F Keating
Journal:  Toxicol Appl Pharmacol       Date:  2012-03-01       Impact factor: 4.219

2.  Utilization of the solid sorbent media in monitoring of airborne cyclophosphamide concentrations and the implications for occupational hygiene.

Authors:  Pavel Odraska; Lenka Dolezalova; Pavel Piler; Michal Oravec; Ludek Blaha
Journal:  J Environ Monit       Date:  2011-04-06

3.  Characterizing the ovotoxicity of cyclophosphamide metabolites on cultured mouse ovaries.

Authors:  Patrice Desmeules; Patrick J Devine
Journal:  Toxicol Sci       Date:  2005-12-28       Impact factor: 4.849

4.  Evidence for a role of chloroethylaziridine in the cytotoxicity of cyclophosphamide.

Authors:  J L Flowers; S M Ludeman; M P Gamcsik; O M Colvin; K L Shao; J H Boal; J B Springer; D J Adams
Journal:  Cancer Chemother Pharmacol       Date:  2000       Impact factor: 3.333

Review 5.  The chemistry of the metabolites of cyclophosphamide.

Authors:  S M Ludeman
Journal:  Curr Pharm Des       Date:  1999-08       Impact factor: 3.116

6.  Detection of DNA damage in oocytes of small ovarian follicles following phosphoramide mustard exposures of cultured rodent ovaries in vitro.

Authors:  Stephanie K Petrillo; Patrice Desmeules; To-Quyen Truong; Patrick J Devine
Journal:  Toxicol Appl Pharmacol       Date:  2011-03-23       Impact factor: 4.219

7.  Trends in 5- and 10-year survival after diagnosis with childhood hematologic malignancies in the United States, 1990-2004.

Authors:  Dianne Pulte; Adam Gondos; Hermann Brenner
Journal:  J Natl Cancer Inst       Date:  2008-09-09       Impact factor: 13.506

8.  Effect of phosphatidylinositol-3 kinase inhibition on ovotoxicity caused by 4-vinylcyclohexene diepoxide and 7, 12-dimethylbenz[a]anthracene in neonatal rat ovaries.

Authors:  Aileen F Keating; Connie J Mark; Nivedita Sen; I Glenn Sipes; Patricia B Hoyer
Journal:  Toxicol Appl Pharmacol       Date:  2009-08-18       Impact factor: 4.219

9.  Cyclophosphamide triggers follicle activation and "burnout"; AS101 prevents follicle loss and preserves fertility.

Authors:  Lital Kalich-Philosoph; Hadassa Roness; Alon Carmely; Michal Fishel-Bartal; Hagai Ligumsky; Shoshana Paglin; Ido Wolf; Hannah Kanety; Benjamin Sredni; Dror Meirow
Journal:  Sci Transl Med       Date:  2013-05-15       Impact factor: 17.956

10.  Premature menopause in survivors of childhood cancer: a report from the childhood cancer survivor study.

Authors:  Charles A Sklar; Ann C Mertens; Pauline Mitby; John Whitton; Marilyn Stovall; Catherine Kasper; Jean Mulder; Daniel Green; H Stacy Nicholson; Yutaka Yasui; Leslie L Robison
Journal:  J Natl Cancer Inst       Date:  2006-07-05       Impact factor: 11.816

View more
  9 in total

1.  Inhibitors of apoptosis protect the ovarian reserve from cyclophosphamide.

Authors:  Yi Luan; Maxwell E Edmonds; Teresa K Woodruff; So-Youn Kim
Journal:  J Endocrinol       Date:  2019-02-01       Impact factor: 4.286

2.  Obesity alters phosphoramide mustard-induced ovarian DNA repair in mice.

Authors:  Shanthi Ganesan; Jackson Nteeba; Jill A Madden; Aileen F Keating
Journal:  Biol Reprod       Date:  2017-02-01       Impact factor: 4.285

3.  Low dosage use of cyclophosphamide improves the survival of patients with systemic lupus erythematosus.

Authors:  Yoosuf Ali Ashraf Muhammad Hussenbocus; Ziyi Jin; Wenyou Pan; Lin Liu; Min Wu; Huaixia Hu; Xiang Ding; Hua Wei; Yaohong Zou; Xian Qian; Meimei Wang; Jian Wu; Juan Tao; Jun Tan; Zhanyun Da; Miaojia Zhang; Jing Li; Xuebing Feng; Lingyun Sun
Journal:  Clin Rheumatol       Date:  2022-03-01       Impact factor: 2.980

Review 4.  The Role of Mutant p63 in Female Fertility.

Authors:  Yi Luan; Pauline Xu; Seok-Yeong Yu; So-Youn Kim
Journal:  Int J Mol Sci       Date:  2021-08-20       Impact factor: 5.923

5.  Phosphoramide mustard exposure induces DNA adduct formation and the DNA damage repair response in rat ovarian granulosa cells.

Authors:  Shanthi Ganesan; Aileen F Keating
Journal:  Toxicol Appl Pharmacol       Date:  2014-12-09       Impact factor: 4.219

6.  Ovarian xenobiotic biotransformation enzymes are altered during phosphoramide mustard-induced ovotoxicity.

Authors:  Jill A Madden; Aileen F Keating
Journal:  Toxicol Sci       Date:  2014-07-28       Impact factor: 4.849

7.  Extended adverse effects of cyclophosphamide on mouse ovarian function.

Authors:  Jihyun Kim; Sooseong You
Journal:  BMC Pharmacol Toxicol       Date:  2021-01-07       Impact factor: 2.483

8.  Protective effects of a SIRT1 inhibitor on primordial follicle activation and growth induced by cyclophosphamide: insights from a bovine in vitro folliculogenesis system.

Authors:  Giovanna Di Emidio; Carla Tatone; Vincenza Barbato; Vincenzo Genovese; Martina Placidi; Riccardo Talevi; Roberto Gualtieri
Journal:  J Assist Reprod Genet       Date:  2022-03-05       Impact factor: 3.357

9.  Chemotherapy drugs cyclophosphamide, cisplatin and doxorubicin induce germ cell loss in an in vitro model of the prepubertal testis.

Authors:  Ellie Smart; Federica Lopes; Siobhan Rice; Boglarka Nagy; Richard A Anderson; Rod T Mitchell; Norah Spears
Journal:  Sci Rep       Date:  2018-01-29       Impact factor: 4.379

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.